277 related articles for article (PubMed ID: 7086705)
1. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
[TBL] [Abstract][Full Text] [Related]
2. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
3. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
6. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
Mais DE; Kochel PJ; Saussy DL; Halushka PV
Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
8. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.
Dangelmaier C; Jin J; Smith JB; Kunapuli SP
Thromb Haemost; 2001 Feb; 85(2):341-8. PubMed ID: 11246558
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
11. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
Le Breton GC; Venton DL; Enke SE; Halushka PV
Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
13. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
14. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
Harris RH; Nichols R; Schmeling JW; Ramwell PW
Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
[No Abstract] [Full Text] [Related]
16. [Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
Mazurov AB; Leĭtin VL; Repin VS
Biull Eksp Biol Med; 1984 Nov; 98(11):563-6. PubMed ID: 6439262
[TBL] [Abstract][Full Text] [Related]
17. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
Turini ME; Holub BJ
Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen binding is independent of an increase in intracellular calcium concentration in thrombin degranulated platelets.
Pulcinelli FM; Daniel JL; Riondino S; Gazzaniga PP; Salganicoff L
Thromb Haemost; 1995 Feb; 73(2):304-8. PubMed ID: 7792747
[TBL] [Abstract][Full Text] [Related]
19. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
20. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
Patscheke H; Stegmeier K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
